Navigation Links
MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
Date:6/23/2011

ROCKVILLE, Md., June 23, 2011  /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protege, the Company's Phase 3 clinical study of teplizumab in type 1 diabetes patients, will be presented at the American Diabetes Association's 71st Scientific Sessions symposium in San Diego, California on June 28, 2011 at 9:10 a.m. PDT.

Dr. Nicole Sherry, Director of the Diabetes Center at Massachusetts General Hospital for Children, and a lead investigator in the Protege study, will be presenting the results of the Phase 3 data as well as the results of exploratory post-hoc analyses.

About Teplizumab

Teplizumab, also called MGA031 and hOKT3gamma1 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and, by doing so, may modulate the pathological immunologic responses underlying multiple autoimmune diseases. Specifically, teplizumab may inhibit unwanted effector T cells and enhance beneficial regulatory T cell functions, thus promoting immune tolerance.  MacroGenics retains full worldwide rights to teplizumab.

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which supports its innovative pipeline of clinical stage product candidates. MacroGenics' proprietary research is based on three core technology platforms, which include: (1) a method for generating cancer stem-like cells; (2) Dual-Affinity Re-Targeting (or DART) technology, which allows the company to incorporate multiple specificities within a single recombinant molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc.  For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.  


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
2. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
5. Watson Announces Expansion of Salt Lake City, Utah Pharmaceutical R&D and Manufacturing Facility
6. Lupin Announces Launch of Generic Levaquin® Tablets
7. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
8. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
9. Oxford BioMedica Announces Ocular Programme Update
10. China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health
11. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Report Details What ... areas are going to grow at the fastest rates? ... assessing data, trends, opportunities and prospects. Our 190-page ... most lucrative areas in the industry and the future ... sales across the all the major categories of the ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... ... for Leading Companies – our new study reveals trends, ... issues and events affecting the Alzheimer,s disease therapeutics and ... answer these key questions: - How is the Alzheimer,s ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, ... anti-obesity drugs market is expected to grow at a CAGR ... CAGR of 38.7% in the second half of the forecast period. ... from 2016 to 2027. The market is estimated at $1,058 million ... ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy Network ... of their 503A compounding pharmacy located in Ocala, Florida. , Meeting the ... patients throughout the United States for high-quality human anti-aging and wellness compounded ...
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic ... in order to make it easier for their readers to get the information they ... impact as well as the techniques used on those particular areas. , “We are ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. ... of Dermatology and fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research ... Li completed his internship in internal medicine at the Emory University and dermatology ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... who administered fillers that resulted in severe facial disfiguration. After four frightening years ... by doctors at UCLA Medical Center, who removed the substances in a partial ...
Breaking Medicine News(10 mins):